Human APOBEC3G-mediated hypermutation is associated with antiretroviral therapy failure in HIV-1 subtype C-infected individuals

Journal of the International AIDS Society

Volumn 16, Issue , 2013, Pages

  Neogi, Ujjwal ^a,b   Shet, Anita ^b   Sahoo, Pravat Nalini ^b   Bontell, Irene ^a   Ekstrand, Maria L ^c   Banerjea, Akhil C ^d   Sonnerborg, Anders ^a,e  

^a KAROLINSKA INSTITUTE   (Sweden)

^b ST JOHN'S NATIONAL ACADEMY OF HEALTH SCIENCES   (India)

^c UNIVERSITY OF CALIFORNIA   (United States)

^d NATIONAL INSTITUTE OF IMMUNOLOGY   (India)

^e KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

Author keywords

Antiretroviral therapy; APOBEC3G F; Drug resistance; Hypermutation; India

Indexed keywords

ANTIRETROVIRUS AGENT; APOLIPOPROTEIN B MESSENGER RNA EDITING ENZYME CATALYTIC POLYPEPTIDE 3G; APOBEC3G PROTEIN, HUMAN; CYTIDINE DEAMINASE; REVERSE TRANSCRIPTASE, HUMAN IMMUNODEFICIENCY VIRUS 1; RNA DIRECTED DNA POLYMERASE; VIRUS DNA; VIRUS RNA;

ADULT; ANTIVIRAL RESISTANCE; ANTIVIRAL THERAPY; ARTICLE; CONTROLLED STUDY; DNA VIRUS; DRUG TREATMENT FAILURE; FEMALE; GENETIC VARIABILITY; GENOTYPE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1 (STRAIN C); HUMAN IMMUNODEFICIENCY VIRUS 1 INFECTION; INDIAN; MAJOR CLINICAL STUDY; MALE; MOLECULAR EVOLUTION; OPEN READING FRAME; PRIORITY JOURNAL; PROVIRUS; RNA EDITING; STOP CODON; STRUCTURAL GENE; VIRUS HYPERMUTATION; VIRUS MUTATION; ANTIRETROVIRAL THERAPY; APOBEC3G/F; DNA SEQUENCE; DRUG EFFECT; DRUG RESISTANCE; GENETICS; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HYPERMUTATION; IMMUNOLOGY; INDIA; MOLECULAR GENETICS; MUTATION; TREATMENT OUTCOME; VIROLOGY;

ANTIRETROVIRAL THERAPY; APOBEC3G/F; DRUG RESISTANCE; HYPERMUTATION; INDIA;

ADULT; ANTI-RETROVIRAL AGENTS; CYTIDINE DEAMINASE; DNA, VIRAL; DRUG RESISTANCE, VIRAL; FEMALE; GENOTYPE; HIV INFECTIONS; HIV REVERSE TRANSCRIPTASE; HIV-1; HUMANS; INDIA; MALE; MOLECULAR SEQUENCE DATA; MUTATION; RNA, VIRAL; SEQUENCE ANALYSIS, DNA; TREATMENT OUTCOME;

MLCS; MLOWN;

EID: 84879152752     PISSN: None     EISSN: 17582652     Source Type: Journal    
DOI: 10.7448/IAS.16.1.18472     Document Type: Article

References (32)

1. Sheehy AM, Gaddis NC, Choi JD, Malim MH. Isolation of a human gene that inhibits HIV-1 infection and is suppressed by the viral vif protein. Nature. 2002;418(6898):646-50.
2. Refsland EW, Hultquist JF, Harris RS. Endogenous origins of HIV-1 G-to-A hypermutation and restriction in the nonpermissive T cell line CEM2n. PLoS Pathog. 2012;8(7):e1002800.
3. Mangeat B, Turelli P, Caron G, Friedli M, Perrin L, Trono D. Broad antiretroviral defence by human APOBEC3G through lethal editing of nascent reverse transcripts. Nature. 2003;424(6944):99-103.
4. Chew CB, Potter SJ, Wang B, Wang YM, Shaw CO, Dwyer DE, et al. Assessment of drug resistance mutations in plasma and peripheral blood mononuclear cells at different plasma viral loads in patients receiving HAART. J Clin Virol. 2005;33(3):206-16.
5. Malim MH. Natural resistance to HIV infection: the vif-APOBEC interaction. C R Biol. 2006;329(11):871-5.
6. Yu Q, Konig R, Pillai S, Chiles K, Kearney M, Palmer S, et al. Single-strand specificity of APOBEC3G accounts for minus-strand deamination of the HIV genome. Nat Struct Mol Biol. 2004;11(5):435-42.
7. Zhang H, Yang B, Pomerantz RJ, Zhang CM, Arunachalam SC, Gao L. The cytidine deaminase CEM15 induces hypermutation in newly synthesized HIV-1 DNA. Nature. 2003;424(6944):94-8.
8. Sadler HA, Stenglein MD, Harris RS, Mansky LM. APOBEC3G contributes to HIV-1 variation through sublethal mutagenesis. J Virol. 2010;84(14):7396-404.
9. Jern P, Russell RA, Pathak VK, Coffin JM. Likely role of APOBEC3G-mediated G-to-A mutations in HIV-1 evolution and drug resistance. Plos Pathog. 2009;5(4):e1000367.
10. Mulder LCF, Harari A, Simon V. Cytidine deamination induced HIV-1 drug resistance. Proc Natl Acad Sci U S A. 2008;105(14):5501-6.
11. Pace C, Keller J, Nolan D, James I, Gaudieri S, Moore C, et al. Population level analysis of human immunodeficiency virus type 1 hypermutation and its relationship with APOBEC3G and vif genetic variation. J Virol. 2006;80(18):9259-69.
12. Land AM, Ball TB, Luo M, Pilon R, Sandstrom P, Embree JE, et al. Human immunodeficiency virus (HIV) type 1 proviral hypermutation correlates with CD4 count in HIV-infected women from Kenya. J Virol. 2008;82(16):8172-82.
13. Ulenga NK, Sarr AD, Hamel D, Sankale JL, Mboup S, Kanki PJ. The Level of APOBEC3G (hA3G)-related G-to-A mutations does not correlate with viral load in HIV type 1-infected individuals. AIDS Res Hum Retroviruses. 2008;24(10):1285-90.
14. Kieffer TL, Kwon P, Nettles RE, Han YF, Ray SC, Siliciano RF. G0A hypermutation in protease and reverse transcriptase regions of human immunodeficiency virus type 1 residing in resting CD4(+) T cells in vivo. J Virol. 2005;79(3):1975-80.
15. Amoedo ND, Afonso AO, Cunha SM, Oliveira RH, Machado ES, Soares MA. Expression of APOBEC3G/3F and G-to-A hypermutation levels in HIV-1-infected children with different profiles of disease progression. PLoS One. 2011;6(8):e24118.
16. Fourati S, Malet I, Lambert S, Soulie C, Wirden M, Flandre P, et al. E138K and M184I mutations in HIV-1 reverse transcriptase co-emerge as a result of APOBEC3 editing in the absence of drug exposure. AIDS. 2012;26(13):1619-24.
17. Neogi U, Prarthana BS, Gupta S, D'Souza G, De Costa A, Kuttiatt VS, et al. Naturally occurring polymorphisms and primary drug resistance profile among antiretroviral-naive individuals in Bangalore, India. AIDS Res Hum Retroviruses. 2010;26(10):1097-101.
18. Neogi U, Bontell I, Shet A, De Costa A, Gupta S, Diwan V, et al. Molecular epidemiology of HIV-1 subtypes in India: origin and evolutionary history of the predominant subtype C. PLoS One. 2012;7(6):e39819.
19. Tamura K, Peterson D, Peterson N, Stecher G, Nei M, Kumar S. MEGA5: molecular evolutionary genetics analysis using maximum likelihood, evolutionary distance, and maximum parsimony methods. Mol Biol Evol. 2011;28(10):2731-9.
20. Rose PP, Korber BT. Detecting hypermutations in viral sequences with an emphasis on G 0A hypermutation. Bioinformatics. 2000;16(4):400-1.
21. Gifford RJ, Rhee SY, Eriksson N, Liu TF, Kiuchi M, Das AK, et al. Sequence editing by apolipoprotein B RNA-editing catalytic component-B and epidemiological surveillance of transmitted HIV-1 drug resistance. AIDS. 2008;22(6):717-25.
22. Bennett DE, Camacho RJ, Otelea D, Kuritzkes DR, Fleury H, Kiuchi M, et al. Drug resistance mutations for surveillance of transmitted HIV-1 drug-resistance: update. PLoS One. 2009;4(3):e4724.
23. Johnson VA, Calvez V, Gunthard HF, Paredes R, Pillay D, Shafer R, et al. 2011 update of the drug resistance mutations in HIV-1. Top Antivir Med. 2011;19(4):156-64.
24. Sen S, Tripathy SP, Chimanpure VM, Patil AA, Bagul RD, Paranjape RS. Human immunodeficiency virus type 1 drug resistance mutations in peripheral blood mononuclear cell proviral DNA among antiretroviral treatment-naive and treatment-experienced patients from Pune, India. AIDS Res Hum Retroviruses. 2007;23(4):489-97.
25. Fourati S, Lambert-Niclot S, Soulie C, Malet I, Valantin MA, Descours B, et al. HIV-1 genome is often defective in PBMCs and rectal tissues after longterm HAART as a result of APOBEC3 editing and correlates with the size of reservoirs. J Antimicrob Chemother. 2012;67(10):2323-6.
26. Hu Z, Kuritzkes DR. Interaction of reverse transcriptase (RT) mutations conferring resistance to lamivudine and etravirine: effects on fitness and RT activity of human immunodeficiency virus type 1. J Virol. 2011;85(21):11309-14.
27. Neogi U, Sahoo PN, De Costa A, Shet A. High viremia and low level of transmitted drug resistance in anti-retroviral therapy-naive perinatally-infected children and adolescents with HIV-1 subtype C infection. BMC Infect Dis. 2012;12(1):317.
28. Ekstrand ML, Shet A, Chandy S, Singh G, Shamsundar R, Madhavan V, et al. Suboptimal adherence associated with virological failure and resistance mutations to first-line highly active antiretroviral therapy (HAART) in Bangalore, India. Int Health. 2011;3(1):27-34.
29. Neogi U, Shet A, Shamsundar R, Ekstrand ML. Selection of nonnucleoside reverse transcriptase inhibitor-associated mutations in HIV-1 subtype C: evidence of etravirine cross-resistance. AIDS. 2011;25(8):1123-6.
30. Diallo K, Murillo WE, de Rivera IL, Albert J, Zhou Z, Nkengasong J, et al. Comparison of HIV-1 resistance profiles in plasma RNA versus PBMC DNA in heavily treated patients in Honduras, a resource-limited country. Int J Mol Epidemiol Genet. 2012;3(1):56-65.
31. Bennett DE, Myatt M, Bertagnolio S, Sutherland D, Gilks CF. Recommendations for surveillance of transmitted HIV drug resistance in countries scaling up antiretroviral treatment. Antivir Ther. 2008;13(Suppl 2):25-36.
32. Neogi U, Heylen E, Shet A, Chandy S, Shamsunder R, Sönnerborg A, et al. Long-term efficacy of first line antiretroviral therapy in Indian HIV-1 infected patients: a longitudinal cohort study. PLoS One. 2013;8(1):e55421.